31 Participants Needed

EEG Markers for ECT Response in Depression

MK
OH
Overseen ByOrlandrea Hyche
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Washington University School of Medicine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 3 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

Single-center study to determine the relationship between changes in depression symptoms and electroencephalographic (EEG) patterns induced by electroconvulsive therapy (ECT)

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is Electroconvulsive Therapy (ECT) safe for humans?

Electroconvulsive Therapy (ECT) is generally considered safe for treating certain psychiatric disorders, though rare complications like heart issues and seizures can occur. It's important for medical staff to be well-trained and monitor patients closely to manage any potential side effects.12345

How is electroconvulsive therapy (ECT) different from other treatments for depression?

Electroconvulsive therapy (ECT) is unique because it involves inducing controlled seizures in the brain to treat severe depression, which is different from medications or talk therapy. It is often used when other treatments have failed, and recent research suggests that EEG (a test that measures brain activity) can help predict which patients will respond well to ECT.46789

What data supports the effectiveness of this treatment for depression?

Research shows that electroconvulsive therapy (ECT) is highly effective for treating severe depression, with 63% of patients showing significant improvement. Additionally, certain brain activity patterns measured by EEG may help predict which patients will respond well to ECT.6781011

Who Is on the Research Team?

MK

MohammadMehdi Kafashan

Principal Investigator

Washington University School of Medicine

Are You a Good Fit for This Trial?

This trial is for adults (18+) referred for ECT to treat resistant depression, including major depressive disorder with or without psychotic symptoms, and those with schizophrenia or schizoaffective disorder currently experiencing a depressed episode.

Inclusion Criteria

I am referred for ECT due to treatment-resistant depression or a related condition.

Exclusion Criteria

I have schizophrenia or schizoaffective disorder and am not currently being treated for depression.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo up to 22 ECT sessions with EEG monitoring to assess depression severity and EEG markers

8 weeks
Up to 22 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after ECT treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Electroconvulsive Therapy (ECT)
Trial Overview The study aims to correlate changes in depression symptoms with EEG patterns following electroconvulsive therapy. It involves measuring post-ictal EEG suppression, sleep microstructure, closed loop acoustic stimulation effects, and using the QIDS-SR16 scale.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Patients with Treatment-Resistant DepressionExperimental Treatment6 Interventions

Electroconvulsive Therapy (ECT) is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Electroconvulsive Therapy for:
  • Severe depression
  • Bipolar disorder
  • Schizophrenia
  • Catatonia
  • Agitation in dementia (off-label)
🇪🇺
Approved in European Union as Electroconvulsive Therapy for:
  • Severe depression
  • Bipolar disorder
  • Schizophrenia
  • Catatonia
  • Agitation in dementia (off-label)
🇨🇦
Approved in Canada as Electroconvulsive Therapy for:
  • Severe depression
  • Bipolar disorder
  • Schizophrenia
  • Catatonia
  • Agitation in dementia (off-label)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials
2,027
Recruited
2,353,000+

Published Research Related to This Trial

In a study of 261 patients undergoing Electroconvulsive Therapy (ECT) over four years, 63% showed significant improvement, indicating ECT can be an effective treatment for severe mental health conditions.
Response to ECT was not predicted by most clinical and neuropsychological assessments, but was associated with factors like history of substance abuse and specific psychiatric ratings, suggesting that individual patient history may play a crucial role in treatment outcomes.
Electroconvulsive treatment--indications, benefits, and limitations.Small, IF., Milstein, V., Miller, MJ., et al.[2018]
Electroconvulsive therapy (ECT) is generally a safe and effective treatment for psychiatric disorders, but it can lead to rare complications such as prolonged seizures, as demonstrated in a case involving an 83-year-old female patient.
In this case, the patient experienced a prolonged seizure lasting about 700 seconds during her third ECT session, highlighting the need for careful monitoring and the development of preventive protocols to manage such risks in future ECT treatments.
Epileptic status as a complication of electroconvulsive therapy: a case report.Reyes-Molón, L., Trebbau-López, H., Saiz-González, D.[2012]
Electroconvulsive therapy (ECT) is recognized as an effective and safe treatment for certain mental health conditions, although some of its uses are based more on professional consensus than solid clinical research.
The effectiveness and side effects of ECT can vary widely among patients, highlighting the importance of understanding individual factors that may influence treatment outcomes.
[Electroconvulsive therapy: indications and improvement].Colin Piana, R.[2006]

Citations

Electroconvulsive treatment--indications, benefits, and limitations. [2018]
Using EEG to Predict Clinical Response to Electroconvulsive Therapy in Patients With Major Depression: A Comprehensive Review. [2021]
Pretreatment neurophysiologic function and ECT response in depression. [2019]
An Electrophysiological Biomarker That May Predict Treatment Response to ECT. [2020]
Neurochemical correlates of rapid treatment response to electroconvulsive therapy in patients with major depression. [2022]
Epileptic status as a complication of electroconvulsive therapy: a case report. [2012]
[Electroconvulsive therapy: indications and improvement]. [2006]
Electroconvulsive therapy: an update. [2019]
The persistence of electroconvulsive therapy-induced changes in the electroencephalogram. [2019]
[Current use of ECT in the treatment of depressive disorders]. [2018]
11.United Statespubmed.ncbi.nlm.nih.gov
EEG correlates of the response to ECT: a possible antidepressant role of brain-derived neurotrophic factor. [2007]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security